Retrophin Announces Addition To The NASDAQ Biotechnology Index
NEW YORK--(BUSINESS WIRE)--Retrophin, Inc. (NASDAQ:RTRX) today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI). The addition will become effective prior to market open on Monday, December 22, 2014.
The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NASDAQ Biotechnology Index is re-ranked annually. In order for companies to be eligible for inclusion on this list, companies must have a minimum market cap of $200 million and a minimum daily trading volume of 100,000 shares. For more information about the NASDAQ Biotechnology Index, please visit www.nasdaq.com.
Help employers find you! Check out all the jobs and post your resume.
The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NASDAQ Biotechnology Index is re-ranked annually. In order for companies to be eligible for inclusion on this list, companies must have a minimum market cap of $200 million and a minimum daily trading volume of 100,000 shares. For more information about the NASDAQ Biotechnology Index, please visit www.nasdaq.com.
Help employers find you! Check out all the jobs and post your resume.